FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW HAVEN, Conn., Jan. 05, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback